Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02494076 · ClinicalTrials.gov registry record · Phase 4

Positive Expiratory Pressure for the Treatment of Acute Asthma in Children

A Phase 4 study of Asthma, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 4
Development phase
52
Enrollment target
1
Study location

NCT02494076 is a Phase 4 study of Asthma that has completed, run by University of Colorado, Denver. The registered enrollment target is 52 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02494076, a Phase 4 study of Asthma, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 4
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

Asthma is a leading cause of emergency department (ED) visits for children. A novel way of treating asthma is the use of positive expiratory pressure (PEP). Positive expiratory pressure works by creating pressure in the lungs to keep airways open and to clear mucus from the lungs. PEP is already used in the treatment of asthma at the investigators institution, but studies evaluating the efficacy of PEP therapy in asthma exacerbations do not exist. This study plans to learn more about the use of PEP therapy in the treatment of asthma exacerbations in children in the emergency department. Specifically, the study aims to evaluate if PEP therapy reduces the severity of asthma exacerbations in children and if it reduces the need for additional therapies and admission to the hospital. This study will be a randomized control trial comparing children who receive standard therapy to those who receive standard therapy plus PEP therapy in the treatment of asthma exacerbations. Children age 2 to 18 years presenting to the ED with moderate to severe asthma exacerbations will be included in the study. Reduction in clinical asthma severity will be measured by change in the Pulmonary Asthma Score (the respiratory severity score used at the investigators institution). The need for additional therapies and hospitalization will also be evaluated.

Conditions Studied

Asthma

Interventions

  • OTHER Standard Care
  • DRUG EzPAP

Study Locations (1)

Colorado

  • Childrens Hospital Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2014-10
Est. Completion 2017-04-12
Phase Phase 4

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02494076

The ClinicalTrials.gov registry entry for NCT02494076 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Standard Care is the first listed.

NCT02494076 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02494076 about?

NCT02494076 is a clinical study titled "Positive Expiratory Pressure for the Treatment of Acute Asthma in Children". Asthma is a leading cause of emergency department (ED) visits for children. A novel way of treating asthma is the use of positive expiratory pressure (PEP). Positive expiratory pressure works by creating pressure in the lungs to keep airways open and to clear mucus from the lungs. PEP is already use...

What is the current status of trial NCT02494076?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2014-10. Estimated completion is 2017-04-12.

What conditions does trial NCT02494076 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02494076?

The interventions under investigation include: Standard Care (OTHER), EzPAP (DRUG).

Who is sponsoring clinical trial NCT02494076?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02494076 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.